BETA PHARMA CANADA INC has a total of 16 patent applications. Its first patent ever was published in 2009. It filed its patents most often in WIPO (World Intellectual Property Organization), Canada and China. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and medical technology are AXELAR AB, RAKVALIA FARMA INK and PHARMACIA ITALIA SPA.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | Canada | 4 | |
#3 | China | 4 | |
#4 | EPO (European Patent Office) | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Medical technology | |
#4 | Biotechnology | |
#5 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds | |
#4 | Electrotherapy | |
#5 | Enzymes | |
#6 | Microorganisms | |
#7 | Special acyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Wang Zhaoyin | 14 |
#2 | Li Lianhai | 8 |
#3 | Yu Chunrong | 4 |
#4 | Wang Zhigang | 4 |
#5 | Yuan Wei W | 2 |
Publication | Filing date | Title |
---|---|---|
CA2863239A1 | Cyclic molecules as bruton's tyrosine kinase inhibitors | |
CN103974956A | Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents | |
CN104039797A | Heterocyclic molecules as apoptosis inducers | |
WO2013013308A1 | Spirocyclic molecules as protein kinase inhibitors | |
WO2013185202A1 | Apoptosis inducers | |
WO2012094451A1 | Novel ureas for the treatment and prevention of cancer | |
EP2320906A1 | Heterocyclic amide derivatives as ep4 receptor antagonists |